Understanding the Gut Microbiome in Type 1 Diabetes and Metformin Action
This study is exploring the gut microbiome (the community of bacteria in your intestines) in young people aged 11-18 with Type 1 Diabetes (T1D). Researchers are looking at how the gut microbiome and its byproducts (metabolites) differ between those who are lean and those who are overweight or obese. The study aims to understand the role of the gut microbiome in T1D, especially when obesity is also present, and how a medication called Metformin might affect this. The main goals are to identify these differences at the beginning of the study. We don't have information on the current recruitment status.
- Study design
- This interventional study plans to enroll 114 participants. It is exploring the effects of Metformin.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Differences in the gut microbiome in lean and overweight/obese youth with type 1 diabetesBaseline
cross sectional comparison of stool microbiome using metagenomic sequencing data
- Differences in the gut microbial metabolites in lean and overweight/obese youth with type 1 diabetesBaseline
The investigators will measure and compare the stool and serum short chain fatty acids using mass spectrometry
- Differences in the gut microbial metabolites in lean and overweight/obese youth with type 1 diabetesBaseline
The investigators will measure and compare the stool and serum secondary bile acids using mass spectrometry
- Changes in the gut microbiome in overweight/obese youth with type 1 diabetes in response to metforminBaseline, Month 3, and Month 6
longitudinal comparison before and after taking metformin for 6 months, stool samples will be collected at baseline, 3 months and 6 months and sequenced for microbiome profile using metagenomic sequencing
- Changes in the gut microbial metabolites in overweight/obese youth with type 1 in response to metforminBaseline, Month 3, and Month 6
The investigators will measure and compare the stool and serum metabolites (short chain fatty acids and secondary bile acids) before, during and after 6 months of daily metformin therapy using mass spectrometry